地舒单抗在骨质疏松症和肿瘤性骨病中的临床应用及挑战综述  

Review in clinical application and challenges of denosumab in osteoporosis and neoplastic bone disease

作　　者：张宁宁 于露 李利平 姜宏卫 ZHANG Ningning;YU Lu;LI Liping;JIANG Hongwei(School of Clinical Medicine of Henan University of Science and Technology,Luoyang,Henan,471003;Department of Endocrinology and Metabolism,Endocrine Metabolism Center of the First Affiliated Hospital of Henan University of Science and Technology,Luoyang,Henan,471003;Henan Key Laboratory of Rare Diseases,Luoyang,Henan,471003;Luoyang Sub-center of National Clinical Research Center for Metabolic Diseases,Luoyang,Henan,471003)

机构地区：[1]河南科技大学临床医学院,河南洛阳471003 [2]河南科技大学第一附属医院内分泌代谢中心内分泌代谢科,河南洛阳471003 [3]河南省罕见病重点实验室,河南洛阳471003 [4]国家代谢性疾病临床医学研究中心洛阳分中心,河南洛阳471003

出　　处：《实用临床医药杂志》2024年第11期144-148,共5页Journal of Clinical Medicine in Practice

基　　金：河南省省直医疗机构医疗服务能力提升工程专科建设项目[豫卫医(2017)66号];洛阳市医疗卫生科研专项项目(2001027A)。

摘　　要：地舒单抗(Dmab)作为一种核因子κB受体活化因子配体(RANKL)抑制剂,具有较好的疗效和安全性。Dmab已被批准用于治疗骨质疏松症(OP)、骨巨细胞瘤(GCTB)、多发性骨髓瘤(MM)以及实体瘤骨转移患者。但在临床实际应用中,Dmab面临着用药疗程、停药序贯、局部复发等问题。本文综述了Dmab在OP和肿瘤性骨病中的临床应用以及挑战,旨在为临床治疗提供依据。Denosumab(Dmab)is a receptor activator of NF-kappaB ligand(RANKL)inhibitor with better efficacy and safety.Dmab has been approved to treat patients with osteoporosis(OP),giant cell tumor of bone(GCTB),multiple myeloma(MM)and bone metastases from solid tumors.However,in clinical practice,Dmab is faced with problems such as drug duration,drug withdrawal sequence and local recurrence.This article reviewed the clinical application and challenges of Dmab in OP and neoplastic bone disease,aiming to provide evidence for clinical treatment.

关 键 词：核因子ΚB受体活化因子配体 地舒单抗 骨质疏松症 骨肿瘤 治疗疗程 

分 类 号：R589.5[医药卫生—内分泌] R452[医药卫生—内科学] R73[医药卫生—临床医学]